Daré Bioscience, Inc., a biopharmaceutical company, has announced positive interim results from its ongoing Phase 3 clinical trial of Ovaprene®, an investigational hormone-free, monthly intravaginal contraceptive. The study aims to evaluate the contraceptive effectiveness, safety, and acceptability of Ovaprene. Interim findings revealed that approximately 9% of participants experienced pregnancy, aligning with the company's expectations from previous studies. No serious safety concerns were identified, with favorable overall tolerability reported. The study's Data Safety Monitoring Board recommended continuing the trial without modifications. Final results and analysis of study endpoints, including the pregnancy rate calculated using the Pearl Index, are anticipated upon the study's completion. Currently, there are no FDA-approved hormone-free, monthly intravaginal contraceptives on the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.